home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Medical Device Complaint Handling: MDR, Reports of Removals and Corrections - Webinar by GlobalCompliancePanel

 
  November 23, 2013  
     
 


GlobalCompliancePanel, Online Training, 161 Mission Falls Lane, Suite 216, Fremont, CA 94539, USA
2013-12-05


Overview:

This presentation will step through the FDA regulations relating to post-market product problems, and give examples of how FDA currently interprets these regulations. Following this presentation, you should be able to decide whether your customer complaint requires not only investigation, but reporting to FDA, and in what format the report should be made, and to which section of the Agency. 


Why Should You Attend :

Many device warning letters contain the complaint that the company has failed to adequately develop and maintain their system for dealing with product problems in the field, and that their response to the 483 pointing out this deficiency was inadequate, usually because it was not accompanied by revised documents, and evidence that personnel were adequately trained on the revised system, and evidence that the revised system was in fact working effectively. One major component of the description usually found lacking is the determination of when and how to notify FDA of the problem and how the company is dealing with it. 

Areas Covered in the Session:

QSR Requirements for Complaint Handling 21 CFR 820.198
Medical Device Reporting 21 CFR Part 803
Reports of Corrections and Removals, 21 CFR Part 806
HCT/P that are devices
Combination Products
Electronic ProductsWhen MDR, When electronic product reporting
Repurchase, Repairs, Replacement

Who Will Benefit:

QA specialist
Complaint Coordinator
Regulatory Specialist
QA manager
QA Trainer
All above in Medical Device companies

 

 
 
Organized by: GlobalCompliancePanel
Invited Speakers:
Anna Longwell is currently principal attorney of the Palo Alto Law firm, Longwell and Associates, which specializes in Food and Drug law. The firm has expertise in US FDA expectations, regulation and law, affecting the development and ultimate marketing of new medical products, drugs, devices and biologics. They have served the regulatory needs of large (>$2 billion/year) divisions of Fortune 500 companies, and small (4 person) biotech start-ups. Prior to establishing the firm, Ms. Longwell was VP of Regulatory affairs for Becton Dickinson, Medical a > $2 billion/annum unit of BD engaged in global manufacture and sale of medical devices, consumer products and OTC drugs. In that context, she participated as regulatory expert in many pre-acquisition due diligence teams. Prior work experience included a division of BD investigating monoclonal antibodies as therapy, and Alza Corporation during the period when they pioneered combination products. 
 
Deadline for Abstracts: 2013-12-05
 
Registration:
Contact Information:
NetZealous LLC,
DBA GlobalCompliancePanel 
161 Mission Falls Lane,
Suite 216, Fremont, CA 94539, USA          
USA Phone:800-447-9407
Fax: 302-288-6884
webinars@globalcompliancepanel.com
http://www.globalcompliancepanel.com


E-mail: support@globalcompliancepanel.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.